Arika Carmel: The placement, reverse split, and dilution path that will shape 2026
Arika Carmel's March 2026 financing is small against its funding needs, but it shapes far more than a temporary cash cushion: the money is contingent on a reverse split, the terms already frame the economics of the next private round, and 2026 will now be read through dilution and governance as much as through sales.
The main article already showed that Arika Carmel improved its operating picture in 2025 without really rebuilding its cash cushion. This follow-up isolates the March 2026 financing because that is where the gap becomes sharpest between the headline and the funding reality: the money is small, the close was still conditional, and the dilution path was already being written in a way that can carry into the next round.
That is also why the transaction matters more than its size. At year-end 2025, cash and short-term investments stood at about NIS 4.1 million, supplier credit stood at about NIS 9.6 million, and near the financial-statement signing date cash and securities were only about NIS 3.9 million. At the same time, management and the board were still grounding the runway in a cash-flow forecast, an efficiency program, deferred payments from the controlling shareholder and a company he controls, inventory that could be sold relatively quickly, and agreements with new customers and distributors. So this is not clean growth capital. It is bridge capital.
- The money was not yet in the company. At the signing date, the conditions precedent had not yet been met, and closing still depended, among other things, on shareholder approval for a reverse split and bylaw amendments.
- The dilution does not stop at 9.6%. The investors also received a right to participate in the first private placement within 12 months at 90% of that future price, with a floor of NIS 0.30 per share.
- This is both a financing deal and a governance deal. The lead investor is supposed to receive a board seat subject to closing and minimum holdings, and the company asked shareholders to adapt the bylaws and board structure accordingly.
What was actually signed in March 2026
On 24 March 2026, the company signed with two investors for a total investment of NIS 2.5 million, split equally, at about NIS 0.226 per share and in exchange for an allotment that would give them about 9.6% of the share capital after the placement, not on a fully diluted basis. At first glance that sounds like a small raise, and it is. But this is not just a share allotment. It is a full financing package.
| Item | What was signed | Why it matters |
|---|---|---|
| Investment amount | NIS 2.5 million | Meaningful cash for the current balance sheet, but not large enough to solve the liquidity question by itself |
| Direct dilution | About 9.6% of post-allotment equity | Even a small round becomes close to double-digit dilution when the equity base is small |
| Share price | About NIS 0.226 | The round was priced at a very low absolute share price, which keeps future share-count sensitivity high |
| Follow-on right | Participation in the first private placement within 12 months at 90% of that price, but not below NIS 0.30 per share | The investors did not buy only this round. They also secured better economics for a future private round |
| Governance layer | A personal board seat for the lead investor subject to minimum holdings | The money comes with board influence, not just cash |
That chart is the core of the story. NIS 2.5 million is meaningful relative to available liquidity, but still small relative to the funding layers already holding the business up. It is smaller than supplier financing, and it sits above an approximately NIS 1.1 million obligation to the controlling shareholder for deferred salary reduction and adaptation pay that was still unpaid at the financial-statement signing date. The right reading is therefore not "the financing issue is solved." It is "the company is trying to buy more time without yet removing its dependence on other funding sources."
Why the reverse split matters more than the headline
The easy point to miss is that the reverse split did not appear here as cosmetic cleanup. It was written in as an explicit condition precedent to the share allotment. The company had already called a special general meeting on 26 March 2026 for 16 April 2026 in order to approve the reverse split and the related bylaw amendments. In other words, until shareholders approve the package, there is no close. And until there is a close, there is no new cash.
That separation matters. The reverse split does not generate one additional shekel of liquidity, does not reduce accumulated losses, and does not by itself improve the cash path. It simply opens the structural gate for the transaction. Anyone reading March 2026 as if the cash were already sitting on the balance sheet is taking too large a shortcut. At the signing date, this was still contingent capital.
The approval package is also wider than the reverse split itself. It included raising the maximum number of directors to 9, granting the lead investor a personal right to appoint one director as long as the investors together hold at least 8% and the lead investor at least 4%, and another bylaw adjustment around board-chair appointment. Shareholders were therefore being asked to approve not only a raise, but a raise bundled with a tailored governance structure.
That chart does not look dramatic at first glance. 9.6% is not a loss of control. But in a micro-cap company with an ongoing need for capital, almost 10% in a single round is already an event, especially when it is paired with a follow-on participation right and a board seat.
The dilution path does not end at 9.6%
The easiest mistake is to think the dilution stops on the allotment date. In practice, the agreement is already writing the economics of the next private placement, if one is needed within 12 months of closing. Each investor gets the right to participate in that first subsequent private placement in line with its holdings, at 90% of the price set there, as long as the price is not below NIS 0.30 per share.
The implication is straightforward. The company did not commit to another round, but it did create a preferred path if another round is required. So the March 2026 placement is not just immediate dilution of about 9.6%. It also identifies who sits with better economics in the next private round if commercialization and regulatory progress do not widen the breathing room by then.
That has to be read on top of an existing dilution layer that was already present at year-end 2025. The company had 104.165 million issued and paid-up shares, alongside 8.090 million options outstanding, of which 5.208 million were already exercisable. So even without another capital raise, 2026 is not starting from a clean equity line. The capital structure already carries an open option layer, and the March placement now adds a private round with a built-in future participation right.
That is exactly where the reverse split and the dilution path connect. The reverse split does not change the company's economics on its own, but it restructures the share base so the current round can actually be completed. If another private placement is then needed, the March investors arrive there with an advantage already written into this agreement.
Why the auditor is pointing attention here
This continuation matters because the placement was signed against a funding backdrop that the filing itself still describes as tight. The auditor drew attention to management's plans in note 1(f), and the company itself described a position where a NIS 5.191 million operating loss, a NIS 5.853 million annual loss, accumulated losses of NIS 84.399 million, and only about NIS 3.9 million of cash and securities near the signing date still required reliance on a cash-flow plan rather than on current operating results alone.
This is where March 2026 connects directly into the funding thesis. Management prepared a cash-flow forecast through 31 December 2027, but the ability to meet obligations still rests on several assumptions at once: efficiency measures, sales forecasts, deferred payments from the controlling shareholder and a company he controls, inventory that can be sold relatively quickly, and agreements with new customers and distributors. The auditor also identified the cash-flow forecast and management plans as a key audit matter. The new investment therefore does not replace that plan. It joins it.
That is the sharp point. If the company had raised an amount large enough to remove the liquidity question for the next two years, March 2026 could be read as a reset point. That is not the case here. The company is adding a relatively small layer of equity, but it still remains dependent on execution of management's plan. The fact that about NIS 1.1 million owed to the controlling shareholder for salary reduction and adaptation pay remained unpaid at the report-signing date shows how much related-party patience is still part of the runway.
Bottom line
The March 2026 transaction looks small because it is small. But in a company like Arika Carmel that is not a side detail. It is the center of the story. This is a transaction that buys time, not one that closes the funding question. It is contingent on a reverse split and bylaw approvals, creates immediate dilution of about 9.6%, opens improved economics for the current investors in a future private round, and adds a governance layer inside the equity package.
So the key question for 2026 is not whether NIS 2.5 million is "a lot" or "a little." The real question is whether that cash, together with the efficiency plan and the existing deferrals, is enough to get the company to its next commercial or regulatory milestone without returning too quickly to the equity market. If yes, March 2026 will look like a reasonable bridge round. If not, the company will have turned out not only to have raised a small amount of capital, but also to have pre-written the dilution economics of the next station.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.